- Status:
- Do Not Prescribe (DNP)
- Decision Date:
- January 2023
Comments
DNP: NICE TA850 - Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
search again